BACKGROUND As CD38 is expressed on red blood cells (RBCs), the plasma of patients on daratumumab (DARA) reacts with the panel cells of pretransfusion tests, masking underlying alloantibodies. The treatment of RBCs with dithiothreitol (DTT) is the most disseminated method to overcome DARA effect on immunohematological tests, but it hampers the identification of potentially harmful antibodies. Our goal was to validate a new strategy, the blockage monoclonal antibody protocol (BMAP), to mitigate the DARA interference on RBCs using anti‐CD38 and antihuman globulin. METHODS Samples of patients receiving DARA were included in the study. Sera were tested using both DTT‐ and BMAP‐treated RBCs, which comprised three steps: 1) titration of monoclonal anti‐CD38, 2) treatment of RBCs obtained from donors with anti‐CD38, and 3) blockage of anti‐CD38–adsorbed RBCs with antihuman globulin. RESULTS Twenty patients were included in the study. Donor RBCs were treated with anti‐CD38 and successfully blocked with antihuman globulin. In 19 patients, DARA‐mediated agglutination was eliminated using both DTT‐ and BMAP‐treated RBCs. In one patient, agglutination persisted when tested against the BMAP‐treated RBCs, and alloantibodies were identified. Patient samples were mixed with commercial anti‐D, ‐C, −e, ‐K, −Jka, ‐Kpb and tested against antigen‐positive BMAP‐treated RBCs, resulting in detection of these antibodies. CONCLUSION This study validated a new strategy to minimize the interference of DARA on immunohematological tests. The protocol preserves the integrity of RBC antigens, permitting the detection of antibodies from all blood group systems. The BMAP has potential use in other situations where specific antibodies may interfere with pretransfusion screening.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.